MonoSol Rx names A. Mark Schobel Chief Innovation & Technology Officer; Keith Kendall assumes role of CEO

Strategic Shift of Executive Resources Expected to Accelerate Advancement of PharmFilm®

Warren, NJ (December 17, 2014) – MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced that Keith Kendall will assume the role of Chief Executive Officer, while Mark Schobel will transition into the newly-created position of Chief Innovation & Technology Officer, effective immediately.

In his new role, Schobel, who joined the Company as CEO in 2005, will lead the Company's intellectual property strategy and internal technology development initiatives to further advance MonoSol Rx's PharmFilm drug delivery technology.

As Chief Innovation & Technology Officer, Mark Schobel said "This strategic shift in executive responsibilities will enable me to interact more directly with the thought leaders in the pharmaceutical industry and help guide the Company's strategic technological and development initiatives to maximize the reach and utility of our PharmFilm drug delivery technology.

In our new positions, both Keith and I will be able to effectively leverage our respective strengths for the benefit of MonoSol Rx, our customers, partners, colleagues and other stakeholders. We have made great progress toward a number of important strategic objectives, and I believe that this new leadership structure will enable us to take the Company to a new level of achievement.  I am confident that these changes position the Company optimally to succeed in the rapidly advancing drug delivery and specialty pharma space, and that my new focus will allow for greater contributions to driving the innovation and evolution of our PharmFilm platform, and that the organization will continue to thrive under Keith's proven leadership."

Kendall, currently the Chief Operating Officer, will oversee the execution of the Company's growth strategy.  "I am grateful for the confidence that our Board has placed in me, and look forward to leading the Company in the next phase of its evolution. Mark and I have worked closely together since I joined MonoSol Rx in 2006, and we look forward to continuing our close collaboration."

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients.  PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs.  The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals — Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence.  For press releases and other company information visit www.monosolrx.com.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-561-1900.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.